Preliminary evidence suggests that GLP-1 RAs, such as exendin-4, can enhance the effectiveness of chemotherapies like gemcitabine in pancreatic cancer, reducing tumour burden more than either treatment alone through complementary antiproliferative and pro-death mechanisms [16]. Here, GLP1R is linked to neoplasm.